Associated Papers
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Liu B et al.
Cancer Medicine, 2022
35393784 (PubMed )
Supplement: CAM4-11-2767-s001.xlsx › Table_S2
Confirming putative variants at ≤ 5% allele frequency using allele enrichment and Sanger sequencing.
Yan YH et al.
Scientific Reports, 2021
34079006 (PubMed )
Supplement: 41598_2021_91142_MOESM2_ESM.xlsx › FFPE
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer.
Yi Z et al.
Npj Breast Cancer, 2020
33145402 (PubMed )
Supplement: 41523_2020_201_MOESM2_ESM.xlsx › Supplementary_Table_1
Select a paper to view details